Based on PeptiDreams PDPS (Peptide Discovery Platform System), the macrocyclic peptide iHA-24 was found effective in preventing both viral infection and viral proliferation in both cell-based experiments and mouse-based animal studies. iHA-24 was also found to exhibit inhibition activity equal to or even higher than that of the current neuraminidase inhibitors. Peptide iHA-24 also exhibited broad influenza strain efficacy against H1N1 (2009 pandemic strain), H5N1 (bird flu, SARS), and H2N2 strains. The drug will now enter clinical studies.
PeptiDream news release, February 8, 2018
PeptiDream ends successfully preclinical trials of iHA-24, an anti-influenza peptide